Researchers demonstrated, using isogenic mouse fibroblasts expressing a single isoform of RAS or mutant KRAS, that RAS/RAP1-specific endopeptidase equally inactivated all isoforms of RAS as well as the major oncogenic KRAS mutants.
[Scientific Reports]